Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Subscribe To Our Newsletter & Stay Updated